IRW-Functionalized Milk-Derived Extracellular Vesicles Promote Osteogenic Recovery in Inflammatory Osteolysis via Modulation of the TXNIP–NRF2 Axis
Pharmaceutics · 11.11.2026 · 18 (11) · 1459
DOI: 10.3390/pharmaceutics18111459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 11.11.2026. Verfasst von Sen Wang und 6 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Foundation of Educational Department of Liaoning Province, Dalian Medical University Young Talent Cultivation Fund Project.
Abstract (Originalsprache)
Background
Inflammatory osteolysis features persistent inflammation and impaired bone formation, requiring therapeutics that concurrently suppress inflammation and promote osteogenesis. Ile-Arg-Trp (IRW), a bioactive tripeptide with anti-inflammatory and pro-osteogenic properties, suffers from poor cellular delivery. Milk-derived extracellular vesicles (MEVs) provide a biocompatible delivery platform to enhance intracellular bioavailability of IRW. We engineered IRW-functionalized MEVs (M-IRW), tested whether MEV delivery amplifies IRW’s dual bioactivity, and elucidated the molecular mechanism.
Methods
The therapeutic effects of M-IRW were evaluated in LPS-stimulated MC3T3-E1 cells and a murine calvarial osteolysis model. Transcriptomic analysis and Geneformer-based virtual knockout identified candidate regulatory pathways, validated by gene silencing, rescue experiments, and reciprocal co-immunoprecipitation. A chronic apical periodontitis model assessed the disease relevance of this pathway.
Results
Nano-flow cytometry and quantitative fluorescence analysis confirmed successful preparation and IRW loading of M-IRW, and M-IRW achieved enhanced cellular association with intracellular accumulation of the labeled IRW formulation relative to free peptide. In LPS-treated MC3T3-E1 cells, M-IRW more potently elevated ALP, RUNX2, and OPN expression than free IRW (p < 0.05). In vivo, M-IRW significantly enhanced osteogenic recovery in calvarial osteolysis, surpassing free IRW (p < 0.05). Transcriptomic analysis identified thioredoxin-interacting protein (Txnip) as a candidate mediator; virtual Txnip knockout predicted NRF2-associated transcriptional enrichment (p < 0.05). Depletion of NRF2 attenuated the osteogenic benefit conferred by both TXNIP knockdown and M-IRW treatment.
Conclusions
M-IRW enables efficient intracellular delivery of IRW and promotes osteogenic repair in inflammatory osteolysis, at least partly through modulation of the TXNIP–NRF2 axis.
Förderung
- National Natural Science Foundation of China
- Foundation of Educational Department of Liaoning Province
- Dalian Medical University Young Talent Cultivation Fund Project
Zitieren
APA
Wang, S., Wu, S., Bai, H., Wang, F., Yu, Y., Niu, W., & Dong, M. (2026). IRW-Functionalized Milk-Derived Extracellular Vesicles Promote Osteogenic Recovery in Inflammatory Osteolysis via Modulation of the TXNIP–NRF2 Axis. Pharmaceutics, 18(11), 1459. https://doi.org/10.3390/pharmaceutics18111459
Vancouver
Wang S, Wu S, Bai H, Wang F, Yu Y, Niu W, et al. IRW-Functionalized Milk-Derived Extracellular Vesicles Promote Osteogenic Recovery in Inflammatory Osteolysis via Modulation of the TXNIP–NRF2 Axis. Pharmaceutics. 2026;18(11):1459. doi:10.3390/pharmaceutics18111459
BibTeX
@article{Wang2026,
author = {Wang, Sen and Wu, Saixuan and Bai, Huicong and Wang, Fang and Yu, Yintao and Niu, Weidong and Dong, Ming},
title = {IRW-Functionalized Milk-Derived Extracellular Vesicles Promote Osteogenic Recovery in Inflammatory Osteolysis via Modulation of the TXNIP–NRF2 Axis},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1459},
doi = {10.3390/pharmaceutics18111459}
}
EUVIMED